Health Secretary Robert F. Kennedy Jr. Faces Intense Congressional Questioning After Seven Hearings in One Week

Health Secretary Robert F. Kennedy Jr. Concluded a week of intensive congressional testimony on April 22, 2026, facing rigorous questioning from senators on vaccines, drug pricing, and departmental priorities as he defended the Trump administration’s proposed budget cuts to the Department of Health and Human Services.

The hearings marked Kennedy’s first appearance before Congress since September 2025 and represented the culmination of seven consecutive days of testimony before various House and Senate committees. Senators from both parties engaged Kennedy on a range of issues, with particular focus on vaccine policy and pharmaceutical industry relations.

During testimony before the Senate Finance Committee and the Senate Committee on Health, Education, Labor and Pensions (HELP), Kennedy emphasized the administration’s efforts to reform dietary guidelines and address what he described as waste, fraud, and abuse within HHS programs. Republicans on the committees praised his leadership as a “breath of fresh air” and encouraged him to highlight recent departmental accomplishments.

Democratic senators, however, expressed significant concern over Kennedy’s approach to vaccine policy, referencing his history of vaccine skepticism prior to joining the administration. They questioned specific decisions to pull back vaccine recommendations and messaging, arguing these actions have contributed to preventable health risks. The senators also pressed Kennedy to disclose details of any agreements made with pharmaceutical companies regarding drug pricing.

Kennedy responded forcefully to criticisms, often raising his voice as he accused Democratic lawmakers of misrepresenting his record and intentions. He maintained that his policy decisions are grounded in scientific evidence and public health objectives, despite opposition characterizing them as politically motivated.

The intense exchanges underscored ongoing tensions between the administration’s health policy agenda and congressional oversight, particularly regarding immunization programs and pharmaceutical regulation. As Kennedy concluded this series of hearings, the debate over the direction of federal health policy under his leadership remains active in Washington.